Phase III Chemoprevention Trial Of Selenium Supplementation In Persons With Resected Stage I Non-Small Cell Lung Cancer

NCT00008385 Phase 3 COMPLETED Results posted

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known if selenium is effective in preventing the growth of new tumors in patients with previously resected non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying selenium to see how well it works compared to a placebo in preventing the development of second primary lung tumors in patients who have undergone surgery to remove stage I non-small cell lung cancer.

Details

Lead sponsor	ECOG-ACRIN Cancer Research Group
Phase	Phase 3
Status	COMPLETED
Enrolment	1772
Start date	2000-12-18
Completion	2019-11

Conditions

• Lung Cancer

Interventions

• placebo
• selenium

Primary outcomes

• Incidence Rate of Second Primary Lung Tumor — Assessed annually for 10 years after randomization
  Incidence rate of second primary lung tumor was defined as the number of new second primary lung tumors per 100 population at risk in a year.

Countries

United States, Canada